Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERO: Relugolix vs leuprolide in advanced prostate cancer
2017-000160-15Phase 3Completed
- Sponsor
- Myovant Sciences
- Start
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tissue-plasminogen activator in prostate cancer (PCa) (2 arms), sponsored by Myovant Sciences. Started Apr 2017; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2017-000160-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000160-15.